About this Research Topic
Mitochondria are pivotal cellular organelles that play a crucial role in regulating metabolism and cell survival, making them a significant focus in the study of blood cancers. The intricate molecular interactions within mitochondria, such as the involvement of the apoptotic machinery and the PINK1-Parkin axis, are essential in understanding their role in various leukemias. Recent studies have revealed that mitochondrial functions and metabolism at the time of diagnosis differ among acute myeloid leukemia (AML) patients, highlighting the potential of mitochondria as therapeutic targets. Furthermore, the differentiation of monocytic AML cells and their mitochondrial functions have been linked to the effectiveness of antileukemic treatments. Despite these advancements, there remains a gap in fully understanding how mitochondrial dysregulation affects treatment outcomes across different blood malignancies, necessitating further investigation into personalized medical approaches.
This Research Topic aims to explore the role of mitochondrial factors in the therapy response and survival of patients with AML and other blood malignancies, such as acute lymphocytic leukemia (ALL), chronic myeloid leukemia (CML), and myelodysplastic syndromes (MDS). The objective is to identify mitochondrial druggable proteins and pathways that could enhance treatment efficacy. By integrating omics technologies, functional assays, and bioinformatics, this research seeks to address key questions about the impact of mitochondrial dysregulation on treatment outcomes and to test hypotheses related to personalized therapeutic strategies.
To gather further insights into the effects of mitochondrial dysregulation on blood cancer treatment, we welcome articles addressing, but not limited to, the following themes:
- The role of oxidative phosphorylation and mitochondrial respiratory complexes in cancer therapeutics.
- Differences in glucose, lipid, sterol, and amino acid metabolism in cancer cells and their impact on treatment efficacy.
- The integration of omics technologies and artificial intelligence in identifying mitochondrial targets.
- Functional assays to validate mitochondrial druggable proteins and pathways.
- Implementation of fast and robust mitochondrial tests in clinical settings.
- Personalized medical approaches based on mitochondrial function and metabolism.
Please note: manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic.
This Research Topic aims to explore the role of mitochondrial factors in the therapy response and survival of patients with AML and other blood malignancies, such as acute lymphocytic leukemia (ALL), chronic myeloid leukemia (CML), and myelodysplastic syndromes (MDS). The objective is to identify mitochondrial druggable proteins and pathways that could enhance treatment efficacy. By integrating omics technologies, functional assays, and bioinformatics, this research seeks to address key questions about the impact of mitochondrial dysregulation on treatment outcomes and to test hypotheses related to personalized therapeutic strategies.
To gather further insights into the effects of mitochondrial dysregulation on blood cancer treatment, we welcome articles addressing, but not limited to, the following themes:
- The role of oxidative phosphorylation and mitochondrial respiratory complexes in cancer therapeutics.
- Differences in glucose, lipid, sterol, and amino acid metabolism in cancer cells and their impact on treatment efficacy.
- The integration of omics technologies and artificial intelligence in identifying mitochondrial targets.
- Functional assays to validate mitochondrial druggable proteins and pathways.
- Implementation of fast and robust mitochondrial tests in clinical settings.
- Personalized medical approaches based on mitochondrial function and metabolism.
Please note: manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic.
Keywords: mitochondria, AML, energy metabolism, antileukemic therapy, antileukemic strategies
Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.
